marijuana stocks news

American Cannabis Company, Inc. (AMMJ)

 

Income Statement Get Income Statement for:
View: Annual Data | Quarterly Data All numbers in thousands
Period Ending Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Total Revenue 640   (3,848) 2,585   1,881  
Cost of Revenue 416 (3,683) 2,180 1,859
Gross Profit 224   (164) 406   22  
Operating Expenses
Research Development 13
Selling General and Administrative 3,588 (1,758) 1,752 283
Non Recurring
Others
Total Operating Expenses
Operating Income or Loss (3,377) 1,594   (1,346) (262)
Income from Continuing Operations
Total Other Income/Expenses Net 96
Earnings Before Interest And Taxes (3,605) 1,497 (1,250) (262)
Interest Expense (1) (82) 49 34
Income Before Tax (3,604) 1,579 (1,299) (296)
Income Tax Expense 12 (65)
Minority Interest
Net Income From Continuing Ops (3,569) 1,526 (1,311) (231)
Non-recurring Events
Discontinued Operations
Extraordinary Items
Effect Of Accounting Changes
Other Items
Net Income (3,604) 1,526   (1,311) (231)
Preferred Stock And Other Adjustments
Net Income Applicable To Common Shares (3,604) 1,526   (1,311) (231)

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Lifeist Wellness Inc. (NXTTF) Reports Third Quarter 2022 Financial Results

Lifeist Wellness Reports Third Quarter 2022 Financial Results Lifeist Wellness Inc. (“Lifeist”…

Innovative Industrial Properties, Inc. (IIPR) Prices Public Offering of 1,578,948 Shares of Common Stock

Innovative Industrial Properties Prices Public Offering of 1,578,948 Shares of Common Stock…

$CBDS CBD Water Now Available

Cannabis Sativa, Inc. Wild Earth Naturals CBD Water Available Now MESQUITE, NV…

AbbVie Inc. (ABBV) Cariprazine (VRAYLAR®) Met Primary Endpoint in Phase 3 Study

AbbVie’s Cariprazine (VRAYLAR®) Met Primary Endpoint in Phase 3 Study as an…